In the face of escalating chronic respiratory diseases across Europe, where conditions like chronic obstructive pulmonary disease (COPD) and cystic fibrosis claim thousands of lives annually, lung transplantation remains the gold standard treatment for end-stage lung failure. Yet, donor organ shortages persist, with Eurotransplant reporting waitlists exceeding capacity and mortality rates climbing during delays. Enter groundbreaking research from Hannover Medical School (MHH) in Germany and the University of Twente (UT) in the Netherlands, pushing the boundaries of artificial lung technology toward extended survival without native lungs.
These institutions, collaborating through German Research Foundation (DFG)-funded initiatives, are developing implantable and integrated devices that could bridge patients to transplant or serve as destination therapy. While a recent U.S. case demonstrated 48-hour lungless survival using a total artificial lung system, European efforts at MHH and UT lay foundational work for long-term viability, addressing biocompatibility, miniaturization, and multi-organ support.
Europe's Lung Crisis: The Urgent Need for Artificial Alternatives
Europe faces a profound lung disease burden, with COPD alone affecting over 36 million people and causing 300,000 deaths yearly, per European Respiratory Society data. Lung transplants, performed at centers like MHH—Europe's largest with over 100 procedures in 2025—save lives but are limited by donor scarcity. Extracorporeal membrane oxygenation (ECMO), the current bridge therapy, supports gas exchange extracorporeally but is plagued by complications: thrombosis in 30-50% of cases, bleeding from anticoagulation, and kidney failure in 70% of patients.
MHH and UT researchers target these gaps. UT's RenOx integrates lung and kidney functions, while MHH's biohybrid lung aims for implantation, potentially enabling weeks or months of support—far beyond ECMO's days.
RenOx at University of Twente: Revolutionizing Integrated Organ Support
The University of Twente's RenOx, spearheaded by Prof. Dr.-Ing. Jutta Arens and PhD graduate Dr. Ana Martins Costa (thesis defended summer 2025), represents a paradigm shift. This compact device merges artificial lung (oxygenation/CO2 removal) and kidney dialysis capabilities, roughly the size of standard ECMO units but with dual functionality.
"Using two separate machines increases both risks and costs," notes Martins Costa. Funded by DFG and developed with RWTH Aachen and MHH, RenOx uses specialized membranes for gas exchange and waste removal, tested with porcine blood to mimic human physiology accurately.
How RenOx Works: A Step-by-Step Breakdown
RenOx operates via a streamlined extracorporeal circuit:
- Step 1: Blood Withdrawal – Venous blood is drawn, similar to ECMO.
- Step 2: Gas Exchange – Hollow fiber membranes oxygenate blood and remove CO2.
- Step 3: Dialysis Integration – Adjacent fibers perform hemodialysis, clearing urea and toxins without separate pumps.
- Step 4: Return to Body – Oxygen-rich, purified blood returns arterially.
Prototype tests confirmed efficient gas transfer and waste removal, reducing setup complexity and infection risks. Collaborators at MHH provide clinical insights from their transplant expertise.
This integration tackles lung-kidney crosstalk, where ECMO-induced inflammation often precipitates renal failure.
Hannover Medical School's Biohybrid Lung: Toward Permanent Implantation
At MHH's Lower Saxony Centre for Biomedical Engineering (NIFE), PD Dr. Bettina Wiegmann leads DFG-funded projects under SPP 2014 "Spanlang" (€1.6M renewed). The biohybrid lung colonizes ECMO-like components—membranes, pumps, tubes—with endothelial cells for thromboresistance and immune evasion.
Key innovations include titanium dioxide-coated membranes and HLA-silenced allogeneic cells. Computer models optimize geometry for 100m² gas exchange surface in minimal volume, adapting to diseases like COPD. Testing progresses from in vitro circuits to animal models.
Learn more about MHH's biohybrid lung projects.Overcoming Key Challenges: Biocompatibility and Beyond
The 2020 review by Arens et al. (UT/MHH-linked) outlines hurdles: clot formation, inflammation, hemolysis. Solutions include NO-releasing surfaces, factor XII inhibitors, and CFD-optimized flows. RenOx/Biohybrid address these via integrated design and cellular linings, promising survival extensions akin to U.S. 48-hour demo but for chronic use.
- Thrombosis risk reduced 50% with endothelialization (MHH data).
- Gas efficiency boosted via multiphase modeling (UT).
- Kidney co-support cuts multi-organ failure by 70%.
Collaborative Synergies: UT-MHH and European Networks
UT's EOST group and MHH's NIFE/LEBAO collaborate via DFG SPP2014 and REBIRTH cluster. Arens (UT) and Wiegmann (MHH) co-author on long-term support. This mirrors EU Horizon efforts like CellMembrane for nanocellulose membranes. MHH's 110 transplants/year (2025) provide real-world validation.
Such partnerships exemplify Europe's strength in biomedical engineering education, training PhDs like Martins Costa in interdisciplinary skills.
Clinical Impacts: Bridging to Transplant and Beyond
RenOx/Biohybrid could extend bridge times from days (ECMO) to weeks, mirroring U.S. 48-hour success where a patient stabilized post-pneumonectomy. For Europe’s 10,000+ waitlisted patients, this means higher transplant success. Long-term, implantation offers mobility, reducing ICU stays costing €2,000/day.
Read the joint UT-MHH review on long-term artificial lungs.Future Outlook: Trials, Commercialization, and Education
Next: Large-animal trials (sheep models) for RenOx/Biohybrid durability. EU funding via EIC Pathfinder could accelerate. UT/MHH train next-gen engineers, with programs in biomechanical engineering vital for Europe's medtech sector (€150B market).
"RenOx makes treatment safer and simpler," says Martins Costa. Wiegmann eyes human trials in 5-10 years.
Stakeholder Perspectives and Broader Implications
Patient groups like European Lung Foundation hail potential for 1M+ COPD sufferers. Ethicists note equity challenges in access. Economically, devices could save €billions in ICU costs. For HE, boosts research jobs at AcademicJobs.com/research-jobs.
UT and MHH's artificial lung advances herald a new era, transforming survival prospects. As prototypes evolve, Europe leads in innovative organ replacement, blending engineering prowess with clinical urgency for healthier futures.
